Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416442 | 0.74 | IDO1 (0.40) | CA12CA1CA3CA4CA6 | |
| SCHEMBL2321239 | 0.73 | IDO1 (0.39) | — | |
| SCHEMBL10427395 | 0.71 | CA1 (0.33) | CA1 | |
| SCHEMBL7689668 | 0.64 | CA12 (0.32) | CA12CA1CA3CA4CA6 | |
| SCHEMBL28759920 | 0.64 | CA12 (0.35) | CA12CA1CA3CA4CA6 | |
| SCHEMBL29385734 | 0.64 | CES1 (0.45) | CA1TDP2 | |
| SCHEMBL249997 | 0.64 | CES1 (0.45) | CA1TDP2 | |
| SCHEMBL6487919 | 0.63 | CES1 (0.43) | CA1TDP2 | |
| SCHEMBL4579905 | 0.63 | KDM4E (0.32) | — | |
| SCHEMBL30862184 | 0.63 | CES1 (0.43) | CA1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | claimed |
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | claimed |
| JP-1299273-A | — | — | None | — | — | JP | disclosed |
| CN-113874371-B | Preparation method of tri-fused ring compound and intermediate thereof | 诺和诺德股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-113874371-A | Preparation method of tricyclic compound and intermediate thereof | 山东亨利医药科技有限责任公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | disclosed |
| EP-1723116-B1 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1943247-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1931635-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-5068334-A | Analgesics and antipyretics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| US-5068334-A | Analgesics and antipyretics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0338228-A3 | USE OF QUINOLINE-2,5-DIONES IN A MEDICAMENT HAVING AN ANALGESIC, ANTIPYRETIC AND/OR ANTIPHLOGISTIC ACTIVITY | Dr. Karl Thomae GmbH (DE) | 1991-07-10 | — | — | EP | disclosed |
| EP-0338228-A3 | USE OF QUINOLINE-2,5-DIONES IN A MEDICAMENT HAVING AN ANALGESIC, ANTIPYRETIC AND/OR ANTIPHLOGISTIC ACTIVITY | Dr. Karl Thomae GmbH (DE) | 1991-07-10 | — | — | EP | disclosed |
| JP-H01299273-A | MEDICINAL COMPOSITION CONTAINING QUINOLINE2,5-DIONE, NEW QUINOLINE2,5-DIONE AND ITS PRODUCTION | DR KARL THOMAE GMBH | 1989-12-04 | — | — | JP | disclosed |
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | CA12 4689/4885CA1 1907/4885CA3 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.